![Rapport Therapeutics Inc](/common/images/company/N_RAPP.png)
PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with...
Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella...
PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious...
PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today the receipt of U.S...
PITTSBURGH, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the...
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious...
PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.39 | 11.5682478219 | 20.66 | 23.67 | 18.855 | 101396 | 20.87771604 | CS |
4 | -0.92 | -3.83813099708 | 23.97 | 28.08 | 18.855 | 152454 | 23.85639818 | CS |
12 | 5.05 | 28.0555555556 | 18 | 28.08 | 18 | 222313 | 23.27901819 | CS |
26 | 5.05 | 28.0555555556 | 18 | 28.08 | 18 | 222313 | 23.27901819 | CS |
52 | 5.05 | 28.0555555556 | 18 | 28.08 | 18 | 222313 | 23.27901819 | CS |
156 | 5.05 | 28.0555555556 | 18 | 28.08 | 18 | 222313 | 23.27901819 | CS |
260 | 5.05 | 28.0555555556 | 18 | 28.08 | 18 | 222313 | 23.27901819 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約